Biocartis enters into collaboration agreement with AstraZeneca and initiates EGFR Liquid Biopsy study

Read Article

Biocartis Group NV has announced that it has entered into a master collaboration agreement with AstraZeneca. The master collaboration agreement enables the collaborative development and commercialisation of Idylla-based molecular tests in support of AstraZeneca’s pharmaceutical products.

The announcement marks a broadening of the existing partnership between Biocartis and AstraZeneca that focussed on demonstrating how the unique features of the Idylla platform can overcome the current complexity and long turnaround time of biomarker testing for lung cancer patients. The prospective study with the tissue-based Idylla EGFR Mutation Test (CE-IVD) under the existing partnership was initiated at more than a dozen sites in several European countries. In addition to the new master collaboration agreement, the two companies have agreed to extend this ongoing study to additional countries within and outside Europe.

The scope of the new master collaboration agreement enables collaborative development and commercialization of projects between Biocartis and AstraZeneca, such as but not limited to, companion diagnostic development projects that may cover any type of indication or biomarker. The first project to be initiated under the new agreement is a study focussed on evaluating if liquid biopsy testing using the Idylla EGFR Mutation Assay (RUO[2]) could provide further benefits to tissue-based EGFR molecular testing.

EGFR mutations are important biomarkers to be studied in Non-Small Cell Lung Cancer (NSCLC). AstraZeneca is marketing Tagrisso (osimertinib) which is a leading lung cancer therapy approved for patients with metastatic NSCLC whose tumours have EGFR mutations. EGFR mutations occur in 10-15 per cent of all NSCLC patients in the US and the EU and in 30-40 per cent of all NSCLC patients in Asia. The Idylla ctEGFR Mutation Assay (RUO2), launched in October 2019, is a liquid biopsy assay which allows the detection of 49 EGFR mutations directly from 2 ml of blood plasma and provides results within approximately 160 minutes.

Herman Verrelst, Chief Executive Officer (CEO), Biocartis, commented, “We are pleased to announce that we are further developing our partnership with AstraZeneca by entering into a master collaboration agreement, with a first project focussed on our newly-launched liquid biopsy Idylla ctEGFR Mutation Assay. Current EGFR molecular diagnostic testing is complex because obtaining high-quality tissue samples is difficult, especially in NSCLC where tumours are often very small, leading often up to several weeks of waiting time before results are available. Liquid biopsy EGFR testing with the Idylla ctEGFR Mutation Assay, operating directly from 2 ml of blood plasma, could overcome these challenges and delivers molecular EGFR mutation information faster and easier.”